404 related articles for article (PubMed ID: 20518582)
21. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.
Dhingra MS; Kundu R; Gupta M; Kanungo S; Ganguly N; Singh MP; Bhattacharya MK; Ghosh R; Kumar R; Sur D; Chadha SM; Saluja T
Vaccine; 2014 Aug; 32 Suppl 1():A117-23. PubMed ID: 25091664
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Salinas B; Pérez Schael I; Linhares AC; Ruiz Palacios GM; Guerrero ML; Yarzábal JP; Cervantes Y; Costa Clemens S; Damaso S; Hardt K; De Vos B
Pediatr Infect Dis J; 2005 Sep; 24(9):807-16. PubMed ID: 16148848
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
27. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
[TBL] [Abstract][Full Text] [Related]
28. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial.
Isanaka S; Langendorf C; McNeal MM; Meyer N; Plikaytis B; Garba S; Sayinzoga-Makombe N; Soumana I; Guindo O; Makarimi R; Scherrer MF; Adehossi E; Ciglenecki I; Grais RF
PLoS Med; 2021 Jul; 18(7):e1003655. PubMed ID: 34214095
[TBL] [Abstract][Full Text] [Related]
29. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland.
Vesikari T; Uhari M; Renko M; Hemming M; Salminen M; Torcel-Pagnon L; Bricout H; Simondon F
Pediatr Infect Dis J; 2013 Dec; 32(12):1365-73. PubMed ID: 24051998
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.
Vesikari T; Karvonen A; Ferrante SA; Ciarlet M
Eur J Pediatr; 2010 Nov; 169(11):1379-86. PubMed ID: 20559656
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study.
Muhsen K; Anis E; Rubinstein U; Kassem E; Goren S; Shulman LM; Ephros M; Cohen D
Clin Microbiol Infect; 2018 Jan; 24(1):53-59. PubMed ID: 28442435
[TBL] [Abstract][Full Text] [Related]
32. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.
Giaquinto C; Dominiak-Felden G; Van Damme P; Myint TT; Maldonado YA; Spoulou V; Mast TC; Staat MA
Hum Vaccin; 2011 Jul; 7(7):734-48. PubMed ID: 21734466
[TBL] [Abstract][Full Text] [Related]
33. Rotavirus vaccines: entering a new stage of deployment.
Nakagomi O; Cunliffe NA
Curr Opin Infect Dis; 2007 Oct; 20(5):501-7. PubMed ID: 17762784
[TBL] [Abstract][Full Text] [Related]
34. Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.
Hemming-Harlo M; Vesikari T; Uhari M; Renko M; Salminen M; Torcel-Pagnon L; Hartwig S; Simondon F; Bricout H
J Pediatric Infect Dis Soc; 2017 Nov; 6(4):317-323. PubMed ID: 27760800
[TBL] [Abstract][Full Text] [Related]
35. Rotavirus vaccine: a cost effective control measure for India.
Kumar A; Goel MK; Jain RB; Khanna P; Vibha V
Hum Vaccin Immunother; 2012 Apr; 8(4):501-4. PubMed ID: 23071989
[TBL] [Abstract][Full Text] [Related]
36. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
37. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
38. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.
Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA
Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143
[TBL] [Abstract][Full Text] [Related]
39. RotaTeq vaccine adverse events and policy considerations.
Geier DA; King PG; Sykes LK; Geier MR
Med Sci Monit; 2008 Mar; 14(3):PH9-16. PubMed ID: 18301365
[TBL] [Abstract][Full Text] [Related]
40. Clinical trials of rotavirus vaccines in Europe.
Vesikari T; Giaquinto C; Huppertz HI
Pediatr Infect Dis J; 2006 Jan; 25(1 Suppl):S42-7. PubMed ID: 16397428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
